Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir

Antiviral Research

Volumn 68, Issue 1, 2005, Pages 27-35

  Doyon, Louise ^a   Tremblay, Sonia ^a   Bourgon, Lise ^a   Wardrop, Elizabeth ^a   Cordingley, Michael G ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

HIV; Resistance; Tipranavir

Indexed keywords

AMPRENAVIR; ATAZANAVIR; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ARTICLE; CROSS RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVE SITE; ENZYME DEGRADATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN FOLDING; VIRUS CHARACTERIZATION; VIRUS CULTURE; VIRUS IDENTIFICATION; VIRUS MUTATION;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, GAG; HIV PROTEASE; HIV-1; HUMANS; IMMUNOGLOBULINS; JURKAT CELLS; MUTATION; PROTEASE INHIBITORS; PYRIDINES; PYRONES; SELECTION (GENETICS); SERIAL PASSAGE; VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 25144487293     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.07.003     Document Type: Article

References (47)

1. A. Adachi, H.E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M.A. Martin Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone J. Virol. 59 1986 284 291
2. N.K.T. Back, A. van Wijk, D. Remmerswaal, M. van Monfort, M. Nijhuis, R. Schuurman, and C.A.B. Boucher In vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors AIDS 14 2000 101 102
3. F. Bally, R. Martinez, S. Peters, P. Sudre, and A. Telenti Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors AIDS Res. Hum. Retroviruses 16 2000 1209 1213
4. B. Berkhout HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness J. Biomed. Sci. 6 1999 298 305
5. A. Carillo, K.D. Stewart, H.L. Sham, D.W. Norbeck, W.E. Kohlbrenner, J.M. Leonard, D.J. Kempf, and A. Molla In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor J. Virol. 72 1998 7532 7541
6. J.H. Condra, W.A. Schleif, O.M. Blahy, L.J. Gabryelski, D.J. Graham, J.C. Quintero, A. Rhodes, H.L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K.E. Squires, P.J. Deutsch, and E.A. Emini In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 374 1995 569 571
7. H.C. Côté, Z.L. Brumme, and P.R. Harrigan Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir J. Virol. 75 2001 589 594
8. G. Croteau, L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors J. Virol. 71 1997 1089 1096
9. C. De Mendoza, and V. Soriano Resistance to HIV protease inhibitors: mechanisms and clinical consequences Curr. Drug Metab. 5 2004 321 328
10. L. Doyon, G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors J. Virol. 70 1996 3763 3769
11. F. Dronda, J.L. Casado, S. Moreno, K. Hertogs, I. Garcia-Arata, A. Antela, M.J. Perez-Elias, L. Ruiz and Larder, B for the NELSANE study Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene AIDS Res. Hum. Retroviruses 17 2001 211 215
12. Y.F. Gong, B.S. Robinson, R.E. Rose, C. Deminie, T.P. Spicer, D. Stock, R.J. Colonno, and P.F. Lin In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632 Antimicrob. Agents Chemother. 44 2000 2319 2326
13. F.L. Graham, and A.J. van der Eb A new technique for the assay of infectivity of human adenovirus 5 DNA Virology 52 1973 456 467
14. K. Hertogs, S. Bloor, S.D. Kemp, C. Van den Eynde, T.M. Alcorn, R. Pauwels, M. Van Houtte, S. Staszewski, V. Miller, and B.A. Larder Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples AIDS 14 2000 1203 1210
15. H. Jacobsen, K. Yasargil, D.L. Winslow, J.C. Craig, A. Krohn, I.B. Duncan, and J. Mous Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959 Virology 206 1995 527 534
16. V.A. Johnson, F. Brun-Vezinet, B. Clotet, B. Conway, R.T. D'Aquila, L.M. Demeter, D.R. Kuritzkes, D. Pillay, J.M. Schapiro, A. Telenti, and D.D. Richman Update of the drug resistance mutation in HIV-1 Topics in HIV Medicine 12 2004 119 124
17. M. Karmochkine, A. Si-Mohamed, C. Piketty, C. Ginsburg, G. Raguin, V. Schneider-Fauveau, L. Gutmann, M.D. Kazatchkine, and L. Belec The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients Antiviral Res. 47 2000 179 188
18. S.D. Kemp, M. Salim, N. Field, P. Dehertogh, K. Hertogs, H. Azijn, M.P. de Bethune, and B.A. Larder Site-directed mutagenesis and in vitro drug selection studies have failed to reveal a consistent genotypic resistance pattern for tipranavir Antiviral Ther. 5 2000 31
19. B.A. Larder, K. Hertogs, S. Bloor, C.H. van den Eynde, W. DeCian, Y. Wang, W.W. Freimuth, and G. Tarpley Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples AIDS 14 2000 1943 1948
20. F. Li, R. Goila-Gaur, K. Salzwedel, N.R. Kilgore, M. Reddick, C. Matallana, A. Castillo, D. Zoumplis, D.E. Martin, J.M. Orenstein, G.P. Allaway, E.O. Freed, and C.T. Wild PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing Proc. Natl. Acad. Sci. U.S.A. 100 2003 13555 13560
21. P. Lorenzi, M. Opravil, B. Hirschel, J.P. Chave, H.J. Furrer, H. Sax, T.V. Perneger, L. Perrin, L. Kaiser, S. Yerly and the Swiss HIV Cohort Study Impact of drug resistance mutations on virologic response to salvage therapy AIDS 13 1999 F17 F21
22. M.F. Maguire, R. Guinea, P. Griffin, S. Macmanus, R.C. Elston, J. Wolfram, R. Richards, M.H. Hanlon, D.J. Porter, T. Wrin, N. Parkin, M. Tisdale, E. Furfine, C. Petropoulos, B.W. Snowden, and J.P. Kleim Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro J. Virol. 76 2002 7398 7406
23. F. Mammano, C. Petit, and F. Clavel Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients J. Virol. 72 1998 7632 7637
24. M. Markowitz, H. Mo, D.J. Kempf, D.W. Norbeck, T.N. Bhat, J.W. Erickson, and D.D. Ho Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor J. Virol. 69 1995 701 706
25. J. Martinez-Picado, A.V. Savara, L. Sutton, and R.T. D'Aquila Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1 J. Virol. 73 1999 3744 3752
26. Mayers D., Leith J., Valdez H., Boucher C.A., Schapiro J., Baxter J., McCallister S., Kohlbrenner V.M., Scherer J., Hall D.B., 2004. Impact of 3 or 4 protease mutations at codons 33, 82, 84 and 90 on 2 week virologic responses to tipranavir, lopinavir, amprenavir and saquinavir all boosted by ritonavir in phase 2B trial BI 1182.51. Antivir. Ther. 9, S163.
27. H. Mo, L. Lu, T. Dekhtyar, K.D. Stewart, E. Sun, D.J. Kempf, and A. Molla Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir Antiviral Res. 59 2003 173 180
28. M. Nijhuis, S. Deeks, and C. Boucher Implications of antiretroviral resistance on viral fitness Curr. Opin. Infect. Dis. 14 2001 23 28
29. M. Nijhuis, R. Schuurman, D. de Jong, J. Erickson, E. Gustchina, J. Albert, P. Schipper, S. Gulnik, and C.A.B. Boucher Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy AIDS 13 1999 2349 2359
30. S. Palmer, R.W. Shafer, and T.C. Merigan Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development AIDS 13 1999 661 667
31. S. Paolucci, F. Baldanti, R. Maserati, F. Castelli, F. Suter, F. Maggiolo, A. Pan, and G. Gerna Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART Antiviral Res. 45 2000 101 114
32. J.A. Partaledis, K. Yamaguchi, M. Tisdale, E.E. Blair, C. Falcione, B. Maschera, R.E. Myers, S. Pazhanisamy, O. Futer, A.B. Cullinan, C.M. Stuver, R.A. Byrn, and D.J. Livingston In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease J. Virol. 69 1995 5228 5235
33. A.K. Patick, H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease Antimicrob. Agents Chemother. 40 1996 292 297
34. C. Piketty, E. Race, P. Castiel, L. Belec, G. Peytavin, A. Si-Mohamed, G. Gonzalez-Canali, L. Weiss, F. Clavel, and M.D. Kazatchkine Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy AIDS 13 1999 F71 F77
35. S.M. Poppe, D.E. Slade, K.T. Chong, R. Hinshaw, R. Pagano, P.J. Markowitz, M. Ho, D.D. Mo, H. Gorman, R.R. 3rd, T.J. Dueweke, S. Thaisrivongs, and W.G. Tarpley Antiviral activity of the dihydropyrone PNU-140690 a new nonpeptidic human immunodeficiency virus protease inhibitor Antimicrob. Agents Chemother. 41 1997 1058 1063
36. E. Race Cross-resistance within the protease inhibitor class Antiviral Ther. 6 2001 29 36
37. J.T. Randolph, and D.A. DeGoey Peptidomimetic inhibitors of HIV protease Curr Top Med Chem 2004 1079 1095
38. L.H. Robinson, R.E. Myers, B.W. Snowden, M. Tisdale, and E.D. Blair HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays AIDS Res. Hum. Retroviruses 16 2000 1149 1156
39. L. Ross, Q. Liao, H. Gao, S. Pham, J. Tolson, K. Hertogs, B. Larder, and M.S. Saag Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy AIDS Res. Hum. Retroviruses 17 2001 1379 1385
40. S. Rusconi, S. La Seta Catamancio, P. Citterio, S. Kurtagic, M. Violin, C. Balotta, M. Moroni, M. Galli, and A. d'Arminio-Monforte Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors Antimicrob. Agents Chemother. 44 2000 1328 1332
41. J.M. Schapiro, M.A. Winters, J. Lawrence, and T.C. Merigan Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations AIDS 13 1999 359 365
42. Schwartz, R., Kazanjian, P., Slater, L., Hathaway, B., Markowitz, M., Wheeler, D., Goldman, M., Drulak, M., McCallister, S., Mayers, D., 2002. Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2). Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, Abstract 562-T.
43. M. Tisdale, R.E. Myers, B. Maschera, N.R. Parry, N.M. Oliver, and E.D. Blair Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors Antimicrob. Agents Chemother. 39 1995 1704 1710
44. T. Watkins, W. Resch, D. Irlbeck, and R. Swanstrom Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors Antimicrob. Agents Chemother. 47 2003 759 769
45. Y.M. Zhang, H. Imamichi, T. Imamichi, H.C. Lane, J. Falloon, M.B. Vasudevachari, and N.P. Salzman Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites J. Virol. 71 1997 6662 6670
46. J. Zhou, X. Yuan, D. Dismuke, B.M. Forshey, C. Lundquist, K.H. Lee, C. Aiken, and C.H. Chen Small-molecule inhibition of Human Immunodeficiency Virus Type 1 replication by specific targeting of the final step of virion maturation J. Virol. 78 2004 922 929
47. Zhou, J., Chen, C.H., Aiken, C., 2004b. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecular maturation inhibitor 3-O-{3′,3′-dimethylsuccinyl}- betulinic acid. Retrovirology 1, 15.